Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Flannigan, G. Michael"'
Autor:
Puri, Rajiv, Palit, V., Loadman, Paul, Flannigan, G. Michael, Shah, T.K., Choudry, G.A., Basu, Saurajyoti, Double, John A., Lenaz, G., Chawla, S., Beer, M., Kalken, C.V., de Boer, R., Beijnen, J.H., Twelves, Christopher J., Phillips, Roger M.
The quinone based bioreductive drug apaziquone (EO9) failed to demonstrate efficacy in previous phase II studies following intravenous administration. We determined the dose of apaziquone that can be safely administered intravesically and explored it
Externí odkaz:
http://hdl.handle.net/10454/4150
Autor:
Basu, Saurajyoti, Brown, John E., Flannigan, G. Michael, Gill, Jason H., Loadman, Paul, Martin, Sandie W., Naylor, Brian, Puri, Rajiv, Scally, Andy J., Seargent, Jill M., Shah, Tariq K., Phillips, Roger M.
NAD(P)H:Quinone oxidoreductase-1 (NQO1) has been implicated in the bioreductive activation of the clinically active anticancer drug Mitomycin C (MMC) and a polymorphic variant of NQO1 which lacks functional enzyme activity (NQO1*2) has been linked wi
Externí odkaz:
http://hdl.handle.net/10454/6401
Autor:
Basu, Saurajyoti, Brown, John E., Flannigan, G. Michael, Gill, Jason H., Loadman, Paul, Naylor, Brian, Scally, Andy J., Seargent, Jill M., Shah, Tariq K., Puri, Rajiv, Phillips, Roger M., Martin, Sandie W.
A central theme within the concept of enzyme-directed bioreductive drug development is the potential to predict tumour response based on the profiling of enzymes involved in the bioreductive activation process. Mitomycin C (MMC) is the prototypical b
Externí odkaz:
http://hdl.handle.net/10454/6409
Autor:
Choudry, Guzanfar A., Hamilton Stewart, P.A., Double, John A., Krul, M.R.L., Naylor, Brian, Flannigan, G. Michael, Shah, Tariq K., Phillips, Roger M.
The indolequinone EO9 demonstrated good preclinical activity but failed to show clinical efficacy against a range of tumours following intravenous drug administration. A significant factor in EO9's failure in the clinic has been attributed to its rap
Externí odkaz:
http://hdl.handle.net/10454/3889
Autor:
Flannigan, G. Michael
Publikováno v:
BMJ: British Medical Journal, 1996 Jun 01. 312(7044), 1478-1478.
Externí odkaz:
https://www.jstor.org/stable/29731926
Autor:
Flannigan, G. Michael
Publikováno v:
Current Opinion in Urology; Nov1995, Vol. 5 Issue 6, pU281-U285, 5p
Autor:
Flannigan, G Michael
Publikováno v:
Current Opinion in Urology; Jan1997, Vol. 7 Issue 1, pU10-U12, 3p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Flannigan, G. Michael
Publikováno v:
Current Opinion in Urology; Jan1996, Vol. 6 Issue 1, pU56-U56, 1p
Autor:
Flannigan, G. Michael
Publikováno v:
Current Opinion in Urology; Mar1995, Vol. 5 Issue 2, pU87-U87, 1p